Rangappagari Pravallika et al



Available online at: <u>http://www.iajps.com</u>

Research Article

PREPARATION AND CHARACTERISATION OF MICROPARTICULATE DRUG DELIVERY SYSTEM OF DIACEREIN

Rangappagari Pravallika¹, Thadakapally Ramchander²

^{1,2} Mother Teresa College of Pharmacy, N.F.C Nagar, Ghatkesar, Medchal, Telangana

Abstract:

The objective of the present study was to prepare and evaluate the floating microspheres of Diacerein. Diacerein microspheres were prepared by ionotropic gelation method using polymers such as HPMC (K 100 M), Carbopol, Ethyl cellulose and sodium alginate. Totally 12 different formulations of Diacerein were prepared by using the above polymers. The microspheres were characterized for entrapment efficiency, floating property by in vitro wash-off test and in-vitro drug release. Theformulation F9 was selected as an ideal formulation based on the in vitro release profile which shows an extended drug release of 95% upto 12 hours 0.1N HCl buffer. Surface morphology (SEM analysis) and drug-polymerinteraction studies (FT-IR analysis) were performed only for the ideal formulation, F9. The microspheres were discrete, spherical in shape and had ideal surface morphology as confirmed by SEM and FT-IR studies indicated the lack of drug-polymer interactions in the ideal formulation, F9. The in vitro release data of all microsphere formulations were plotted in various kinetic equations to understand the mechanisms and kinetics of drug release. The ideal formulation, F9 followed first order kinetics and value of "n," is calculated to be 0.7187 indicated that the drug release shows Non-Fickian diffusion.

Keywords: HPMC (K 100 M), Carbopol, Ionotropic gelation method, Diacerein, Sodium Alginate, Ethyl Cellulose.

Corresponding author:

Thadakapally Ramchander, *Mother Teresa College of Pharmacy, N.F.C Nagar, Ghatkesar, Medchal, Telangana*



Please cite this article in press Rangappagari Pravallika et al, **Preparation And Characterisation Of** *Microparticulate Drug Delivery System Of Diacerein*, Indo Am. J. P. Sci, 2023; 10 (08).

INTRODUCTION:

Nowadays conventional dosage forms of drugs are rapidly being replaced by the new and novel drug delivery systems, among these sustained release or control release dosage forms are very popular in present day therapy [1]. Oral route of drug administration is the most suitable and commonly used method of drug delivery but this route more often produces gastric emptying rate that varies from person to person with a short stomach transit time and the existence of large absorption window in the upper small intestine for several drugs [2].

Floating systems are low-density systems that have adequate buoyancy to float over the gastric content and remain buoyant in the stomach without affecting gastric emptying rate for an extended period of time, which results in a augmented gastric retention time and a better control of fluctuation in plasma drug concentration [3,4]. After release of drug, the residual system is emptied from the stomach. These difficulties have encouraged researchers to design a drug delivery system which can stay in the stomach for prolonged and predictable period [5]. Attempts are being made to develop a drug delivery system which can provide therapeutically effective plasma drug concentration for a longer period, thereby reducing the dosing frequency and minimizing fluctuation in plasma drug concentration at steady state by delivering the drug in a controlled and reproducible manner [6,7].

Diacerein or Diacetylrhein comes under the class anthraquinone derivative. Chemically it is 9,10-Table 1: FORMUL ATIC dihydro-4,5-dihydroxy-9,10- dioxo-2-anthranoic acid diacetate1. Diacerein is thought to act via inhibition of interleukin-1Beta, a protein involved in the inflammation and destruction of cartilage that play a role in the development of symptoms of degenerative disease like osteoarthritis [8]. Diacerein is a short acting drug, practically insoluble in water. Oral bioavailability of Diacerein is about 35 to56%. Hence, the drug was selected for preparation of sustained release formulation. The study design was to prepare microsphere of Diacerein by ionotropic gelation method with HPMC and ethyl cellulose as polymers [9,10].

MATERIALS AND METHODS:

Materials

Diacerein was purchased from Hetero Drugs Pvt. Ltd. HPMC K100, Sodium Alginate, Carbopol, Ethyl cellulose was purchased from SDFL Chemicals, Mumbai.

Methods

FORMULATION OF FLOATING MICROSPHERES OF DIACEREIN

For Diacerein microspheres HPMC K100 and Sodium alginate were conceded over the sieve no 40. The floating microspheres were prepared by ionotropic gelation method [11,12]. It was then collected by filtration and allowed to dry in a desiccator for about 24 hours. The formed microspheres were then subjected to evaluation studies.

| Ingredients (mg) | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 | F12 |
|-----------------------|----|----|----|-----|----|----|----|-----|----|-----|-----|-----|
| (mg) API | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
| Sodium | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
| Alginate | | | | | | | | | | | | |
| HPMC K100 | 25 | 50 | 75 | 100 | | | | | | | | |
| | | | | | | | | | | | | |
| Carbopol 934 P | | | | | 25 | 50 | 75 | 100 | | | | |
| Ethyl cellulose | | | | | | | | | 25 | 50 | 75 | 100 |
| NaHCO ₃ | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| CaCl ₂ (g) | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |

Table 1: FORMULATION TABLE OF DIACEREIN

EVALUATION OF FLOATING MICROSPHERES OF DIACEREIN: Pre formulation Parameters

Melting point:

The purity of the obtained drug sample was determined by associating the melting point of the obtained sample with that of the official standards [13].

Drug-Excipient Interaction studies: FT-IR:

The infrared spectra of the pure medicine Diacerein and optimised formula were captured between 400 and 4000 cm. An FTIR spectrophotometer was used to obtain the IR spectra using the KBr disc method [14].

Post formulation parameters Percent yield:

The percentage yield of Diacerein in the formulated product is determined by using the formula:

Weight of the formulation X100 Theoretical weight of drug and polymer

Particle size:

The test is performed to determine the uniformity of the prepared formulation. The particle size of each formulation was determined using optical microscopy technique were diameter of 100 particles each was recorded to determine the average particle size of each formulation [15].

Floating lag Time:

When microspheres are added to a dissolution medium that simulates stomach fluid without pepsin, at pH 1.2, temperature 37 °C, and paddle rotation of 50 rpm, the time it takes for the microspheres to upsurge to the surface of the liquid is measured using a timer [16].

Total floating time:

The time engaged by the microspheres to float continually on the surface of the gastric fluid without pepsin, at pH 1.2, temprature37 °C, paddle rotation at 50 rpm, it is measured using stopwatch [17].

Determination of swelling index:

A dose unit's swelling index was calculated by examining its weight increase. By adding the microspheres to 10ml of 0.1N HCl in a petri dish, the swelling index of a microsphere was calculated. Each microsphere was taken out after every hour for a total of up to 12 hours, blotted with tissue paper to remove any extra water, and weighed on a balance. For each time point, the experiment was carried out three times [18]. The swelling index was derived from the equation and expressed as a percentage

Swelling index (S.I) = {(Wt-Wo/Wo} x 100

Where

Wt = Weight of microspheres at time tWo = weight of microspheres before immersion.

Drug Entrapment Efficiency:

The drug entrapment efficiency of the prepared formulations was assessed by taking 20mg of the prepared microspheres and triturating with 100ml of 0.1N HCl and allowed to stand [19]. The concentration of the drug present is calculated by recording the absorbance and concentration of each formulation.

Concentration of drug in sample Total concentration of drug

Dissolution studios

Drug Dissolution studies:

The rotating paddle method of the USP XX1V apparatus was used to conduct the dissolution test. A 50 rpm stirring speed was used. The dissolution medium (900ml) contained 0.1 N HCL. The temperature was kept at $37\pm 5^{\circ}$ c.At regular intervals, 5 ml samples were taken out, filtered, and replaced with 5 ml of fresh dissolving medium [20]. A double beam UV spectrometer was used to analyse the collected samples for the presence of diacerein at 268 nm after being appropriately diluted with dissolving fluid as needed.

Shape and Surface Morphology (SEM):

Scanning electron microscopy was used to study the microspheres' morphology [21].

Kinetics and Mechanism of Release Analysis

Data from drug release investigations conducted in vitro were plotted in several kinetic models to evaluate release kinetic [22]. Zero order equation

% drug released = kt

First order equation Log % unreleased = kt/2.303

$$\label{eq:Korsmeyer} \begin{split} & Korsmeyer - Peppas \ equation \\ & M_t \ / \ M_\infty = k t^n \end{split}$$

where M_t / M_∞ signifies the portion of drug release at time t, k is the release rateconstant and n is the diffusion coefficient. or

Log drug released = $\log k + n \log t$ Higuchi equation % drug released = $kt^{0.5}$

STABILITY STUDIES:

The stability studies of optimized formulations F9 was achieved at accelerated condition of $40^{\circ}C \pm 2^{\circ}C$, 75% RH conditions for a time of 1 month. The microspheres were withdrawn at every week and evaluated for the percent entrapment efficiency [23]. Samples were analysed after 1 month for their entrapment efficiency.

RESULTS AND DISCUSSION:


Determination of Purity:


The determination of purity was done by performing melting point study compared with that of the official standards. The melting point of the drug Diacerein was found to be $230 \,^{\circ}$ C.


COMPATIBILITY STUDIES

The free drug and the microspheres' FT-IR spectra were both captured. The drug-excipient compatibility experiments show that there are no physical alterations in the drug and polymer mixes. To determine whether there had been any changes in the frequency of functional groups in microspheres with respect to the respective functional group of the drug, the IR spectra of the drug, drug-excipient mixture, and microsphere formulation were compared.

The fact that the main IR absorption peaks in the drug's spectrum were similar to those in the spectrum of the microspheres suggests that there is no contact amid the drug and the polymer, according to spectral studies. The fact that both the polymer and the preparation technique did not alter the drug stability is supported by the similar peaks that correspond to the functional groups and characteristics. The photos below display FTIR graphs of diacerein and an optimised formulation.







PERCENTAGE YIELD

As the drug: polymer ratio augmented, the percentage yield also increased. The low yield in some formulations may be due to adhesion of microspheres to the beaker throughout the formulation process or microspheres misplaced during the washing process. The % yield of Formulations F1 to F12 was between 13% to 30%.

| Table 2: Percentage yield of all formulations | | | | | |
|---|---------------|--|--|--|--|
| FORMLATION | PERCENT YIELD | | | | |
| F1 | 13.70% | | | | |
| F2 | 13.90% | | | | |
| F3 | 17.80% | | | | |
| F4 | 24.08% | | | | |
| F5 | 16.37% | | | | |
| F6 | 19.80% | | | | |
| F7 | 24.20% | | | | |
| F8 | 17.90% | | | | |
| F9 | 26.70% | | | | |
| F10 | 21.80% | | | | |
| F11 | 13.80% | | | | |
| F12 | 28.60% | | | | |

ANALYSIS OF PARTICLE SIZE

By using optical microscope, several formulations' particle sizes were evaluated. The range of 816 to 1292.7 m was found to be the typical particle size. According to the type of polymer employed to prepare the microspheres, the mean particle size greatly differed; this could be because the viscosity of the polymer solution varied. With an increase in polymer concentration, the microspheres' particle size and drug entrapment effectiveness both went up.

| FORMULATION | AVERAGE PARTICLE SIZE |
|-------------|-----------------------|
| F1 | 797.6µm |
| F2 | 956 μm |
| F3 | 819.2 μm |
| F4 | 862.04 μm |
| F5 | 849 μm |
| F6 | 906 µm |
| F7 | 764.622 μm |
| F8 | 767.38 μm |
| F9 | 816 μm |
| F10 | 1292.7 μm |
| F11 | 1112 μm |
| F12 | 1216.7 μm |

FLOATING LAG TIME:

When microspheres are added to a dissolution medium that simulates stomach fluid without pepsin, at pH 1.2, temperature 37 °C, and paddle rotation of 50 rpm, the time it takes for the microspheres to rise to the surface of the liquid is measured using a timer. The floating lag time in the other formulations is less than 5 seconds, in contrast to the formulations F4, F10, F11, and F12 which showed no floating.

| FORMULATION | FLOATING LAG TIME | | | | | | |
|-------------|-------------------|--|--|--|--|--|--|
| F1 | 5 sec | | | | | | |
| F2 | 7sec | | | | | | |
| F3 | 5sec | | | | | | |
| F4 | No floating | | | | | | |
| F5 | 5sec | | | | | | |
| F6 | 5sec | | | | | | |
| F7 | 5sec | | | | | | |
| F8 | 5sec | | | | | | |
| F9 | 5sec | | | | | | |
| F10 | No floating | | | | | | |
| F11 | No floating | | | | | | |
| F12 | No floating | | | | | | |

Table 4: Floating lag Time of all formulations

TOTAL FLOATING TIME:

At pH 1.2, 37°C, and a paddle rotation speed of 50 rpm, the time for the microspheres to float continuously on the surface of the stomach fluid without pepsin is measured using a stopwatch. According to the findings, the total floating time for formulations F7, F8, and F9 was high.

| FORMULATIONS | TOTAL FLOATING TIME |
|--------------|---------------------|
| F1 | 45 minutes |
| F2 | 40 minutes |
| F3 | 1 hour 25 minutes |
| F4 | • |
| F5 | 48 Minutes |
| F6 | 2 hours51 minutes |
| F7 | >3 hours |
| F8 | >3 hours |
| F9 | >3 hours |
| F10 | - |
| F11 | - |
| F12 | - |

| Table 5: Total floating | g time of all | formulations |
|-------------------------|---------------|--------------|
|-------------------------|---------------|--------------|

DEGREE OF SWELLING:

Swellability is a characteristic that indicates how quickly a medication solution will be available for diffusion with higher flux. From the results, it can be inferred that as polymer concentration rises, so does swelling intensity. The swelling index ranged from 5 to 40% for the various formulations from F1 to F12. The F12 formulation, which uses sodium alginate and HPMC as polymers, caused the most swelling.

| FORMULATIONS % swelling index | | | | | | | |
|-------------------------------|--|--|--|--|--|--|--|
| % swelling index | | | | | | | |
| 5 | | | | | | | |
| 15 | | | | | | | |
| 5 | | | | | | | |
| 5 | | | | | | | |
| 3 | | | | | | | |
| 2 | | | | | | | |
| 35 | | | | | | | |
| 30 | | | | | | | |
| 10 | | | | | | | |
| 20 | | | | | | | |
| 10 | | | | | | | |
| 40 | | | | | | | |
| | | | | | | | |

 Table 6: Swelling index of all formulations

DRUG ENTRAPMENT EFFICIENCY:

Diacerein floating microspheres had a drug entrapment effectiveness that ranged from 27% to 110%. With an increase in the amount of the polymers, the produced microspheres' ability to trap drugs improved over time.

The viscosity of the dispersed phase increases as the polymer concentration rises. With increasing viscosity, the particle size grows exponentially. At the maximum polymer concentration, it would be anticipated that the higher viscosity of the polymer solution would reduce drug diffusion into the exterior phase, increasing entrapment efficiency.

| Table 7: % Entrapment efficiency | | | | | | | | |
|----------------------------------|--------|--|--|--|--|--|--|--|
| FORMULATION | % EE | | | | | | | |
| F1 | 75% | | | | | | | |
| F2 | 95% | | | | | | | |
| F3 | 27.5% | | | | | | | |
| F4 | 56.25% | | | | | | | |
| F5 | 29.75% | | | | | | | |
| F6 | 42.5% | | | | | | | |
| F7 | 50% | | | | | | | |
| F8 | 40% | | | | | | | |
| F9 | 56% | | | | | | | |
| F10 | 110% | | | | | | | |
| F11 | 45% | | | | | | | |
| F12 | 37.5% | | | | | | | |

IN-VITRO DRUG RELEASE STUDY:

In-vitro dissolution study of Diacerein from prepared microspheres showed a biphasic mechanism. The release of Diacerein from microspheres was considered by an initial phase of burst effect (higher release), which was owing to the occurrence of drug particles on the surface of the microspheres shadowed by a second phase of moderate release. It has been pragmatic that the sustained release action was greater in formulations containing higher concentration of the rate controlling polymers. The *in vitro* release profile of Diacerein from microspheres displayed that with increasing the concentration of drug: polymer, the release of the Diacerein from the polymer matrix was retarded. The cumulative percent drug release of Optimized formulation F9 was found to be 95.45 % at 180 min.

| TIME | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 | F12 |
|------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 10.90 | 12.72 | 6.36 | 10 | 12.72 | 20 | 21.81 | 9.09 | 9.09 | 9.09 | 10.90 | 8.18 |
| 10 | 22.72 | 17.27 | 10 | 12.72 | 15.45 | 23.63 | 28.18 | 19.09 | 16.36 | 13.63 | 12.72 | 10.90 |
| 15 | 27.27 | 20.90 | 15.45 | 14.54 | 22.72 | 29.09 | 27.27 | 20 | 19.09 | 26.36 | 18.18 | 151.45 |
| 20 | 33.63 | 29.09 | 30.90 | 16.36 | 27.27 | 37.27 | 33.63 | 31.81 | 20.90 | 33.63 | 21.18 | 36.36 |
| 25 | 40.90 | 37.27 | 38.18 | 19.09 | 30.90 | 54.54 | 60 | 46.36 | 46.36 | 55.45 | 28.18 | 71.81 |
| 30 | 47.27 | 44.54 | 46.36 | 36.36 | 38.18 | 60.90 | 71.81 | 72.72 | 79.09 | 62.72 | 42.72 | 73.63 |
| 45 | 62.72 | 50 | 57.27 | 47.27 | 45.45 | 60.90 | 73.63 | 73.63 | 80.90 | 71.81 | 55.45 | 75.45 |
| 60 | 80.90 | 64.54 | 65.45 | 55.45 | 51.81 | 62.72 | 80.90 | 73.63 | 84.54 | 72.72 | 66.36 | 84.54 |
| 120 | 82.72 | 64.54 | 66.36 | 65.45 | 55.45 | 62.72 | 81.81 | 73.63 | 86.36 | 73.63 | 79.09 | 82.72 |
| 180 | 82.72 | 64.54 | 71.81 | 70 | 55.45 | 62.72 | 82.72 | 73.63 | 95.45 | 73.63 | 84.54 | 88.18 |

Tables 8: In-vitro dissolution study Diacerein floating microspheres




Fig 1: In-vitro dissolution study Diacerein floating microspheres F1-F3




Fig 2: In-vitro dissolution study Diacerein floating microspheres F4-F6




Fig 3: In-vitro dissolution study Diacerein floating microspheres F7-F9




Fig 4: In-vitro dissolution study Diacerein floating microspheres F10-F12

KINETIC RELEASE MODELS:

Order of Release Kinetics of Formulations F1-F12:

For the purpose of understanding the linear relationship, or kinetic principles, the release data for diacerein were transformed into graphs. Regression analysis of the data was performed using statistical MS-Excel algorithms. A perusal to Table 9 considering the correlation coefficient (R^2) values obtained showed that all the formulations (F1 to F12) had highest R^2 values for First order plots indicating that the dissolution data fits into First order equation when compared to Zero order equation and R^2 values.

| Tables 9: Release kinetics data | | | | | | | | | |
|---------------------------------|---|--|--|--|--|--|--|--|--|
| zero order | first order | | | | | | | | |
| 0.6334 | 0.7019 | | | | | | | | |
| 0.682 | 0.777 | | | | | | | | |
| 0.647 | 0.754 | | | | | | | | |
| 0.7911 | 0.8808 | | | | | | | | |
| 0.6468 | 0.713 | | | | | | | | |
| 0.4219 | 0.4666 | | | | | | | | |
| 0.528 | 0.6463 | | | | | | | | |
| 0.5183 | 0.557 | | | | | | | | |
| 0.5923 | 0.8181 | | | | | | | | |
| 0.4991 | 0.5697 | | | | | | | | |
| 0.8015 | 0.9343 | | | | | | | | |
| 0.5031 | 0.6526 | | | | | | | | |
| | 0.6334 0.682 0.647 0.7911 0.6468 0.4219 0.528 0.5183 0.5923 0.4991 0.8015 | | | | | | | | |

| Tables 9: Release kinetics data | |
|---------------------------------|--|
|---------------------------------|--|




Fig 5: Zero order and First order plot release kinetics data


RELEASE MECHANISMS:

From the results obtained all the formulations (F1-F12) having the slope (n) value between 0.36 and 0.74. This indicates that these formulations follow release according to Fickian diffusion, while other formulations showed non fickian diffusion kinetics having 'n' value greater than 0.45 as shown in table 5.9.

Considering the correlation coefficient (R) values obtained from the different kinetic equations, the drug release from the most of the all formulations (F1 to F12) were found to follow first order and kosemeyerspeppas release model.

| formulations | Higuchi | Hixon crosswel | kosemeyers-peppas | N value |
|--------------|---------|----------------|-------------------|---------|
| F1 | 0.8513 | 0.6816 | 0.8948 | 0.514 |
| F2 | 0.8801 | 0.7526 | 0.9108 | 0.5757 |
| F3 | 0.8424 | 0.7192 | 0.8472 | 0.722 |
| F4 | 0.9128 | 0.8523 | 0.906 | 0.6402 |
| F5 | 0.8692 | 0.6901 | 0.9089 | 0.4586 |
| F6 | 0.6862 | 0.4527 | 0.766 | 0.3602 |
| F7 | 0.7628 | 0.6007 | 0.7997 | 0.4359 |
| F8 | 0.737 | 0.5584 | 0.8054 | 0.6312 |
| F9 | 0.772 | 0.733 | 0.8195 | 0.7187 |
| F10 | 0.733 | 0.5466 | 0.7829 | 0.6189 |
| F11 | 0.9294 | 0.8951 | 0.9326 | 0.6654 |
| F12 | 0.71 | 0.5963 | 0.7518 | 0.7415 |

Table 10: Polesce kinetics mechanism date





From the obtained release kinetics data, it can be observed that all formulations show first order kinetics i.e. rate of drug release is concentration dependent, followed by kosemeyers-peppas release mechanism, followed by non fickian diffusion properties with respect to n values obtained.

The optimised formulation F9 shows first order release kinetics, Kosmeyers-peppas model release mechanism with non-fickian diffusion property

STABILITY STUDIES:

The stability studies of optimized formulations F9 was accomplished at accelerated condition of $40^{\circ}C \pm 2^{\circ}C$, 75% RH conditions for a period of 1 months. The microspheres were withdrawn at every week and assessed for the percent entrapment efficiency. Samples were analyzed after 1 months for their entrapment efficiency. The entrapment efficiency of the optimized formulation at the end of a months

stored at accelerated stability conditions 40 ± 2 ^oC, 75 \pm 5 % RH was 80.08 %. Also, there was no change in physical appearance and colour change in the formulations. This showed that the formulations are stable at the stored conditions. Therefore shelf-life of the optimized formulation F9 in all possibility is expected to be more than two years.

CONCLUSION:

The current work involves the formulation and invitro estimation of floating microspheres_containing Diacerein for sustained release. By means of polymers such as Sodium alginate and HPMC K100M for the sustained release matrix. Diacerein has absorption window in the upper part of the GI tract. Due to this reason this formulation was designed as floating microspheres. Floating may enhance the absorption of Diacerein. There was no physical incompatibility among the drug and other excipients, according to pre-formulation investigations for drug excipient compatibility. The percentage yield, particle size, swelling index, entrapment effectiveness, floating time, and total floating time of each formulation were all assessed. According to the findings, the final mixture of the two medicines and excipients exhibited sustained release characteristics. All of the formulations' drug content and drug release were evaluated, and all estimated parameters were determined to be in limits, indicating that all of the prepared formulations were effective. For buoyancy characteristics such floating lag time & total floating time, all formulations underwent testing. With the exception of F4, F10, F11, and F12, all formulations produced good outcomes. Drug release in vitro tests were conducted on all formulations. The improved formulation F9 produced the superior result.

REFERENCES:

- 1. Kumar KR. Floating Microspheres: A Novel Approach in Drug Delivery. J Drug Delivery Res., 2012; 1(4): 1-20.
- Manivannan R, Baig MA, Purushothaman M, Kumar NS. Formulation and Evaluation of Eletriptan Hydrobromide Microspheres by using Natural Polymers. Int J Pharm Drug Analysis, 2014; 2(3): 347-53.
- 3. Revathi S, Madhulatha V, Dhanaraju MD. Formulation and Evaluation of Stavudine loaded Sodium Alginate Beads by Ionotropic Gelation Method. Int Res J Pharm, 2014; 5(9): 706-12.
- 4. Fries A, Anthony RW, Cseko A, Gaither CC,

Schulman E . The price and purity of illicit drugs: IDA-P-4332. Institute for Defense Analyses, Virginia, USA, 1981-2007.

- 5. Kapoor D, Vyas RB, Lad C, Patel M, Sharma S. Formulation and evaluation of stomach specific Floating tablet of anti-ulcer drug. World J Pharm and Pharm Sci., 2014; 3(5): 1534-45.
- 6. Lachman L, Liberman HA, Kang JL. The theory and practice of industrial pharmacy. 3rd ed. Varghese publication house, 1991; 296-302.
- Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm, 1996; 136: 117-139.
- 8. Amit Kumar Nayak, Ruma Maji, Biswarup Das. Gastro retentive drug delivery systems: a review, Asian Journal of Pharmaceutical and Clinical Research, 2010; 3(1): 2-10.
- Manisha P, Ranjava G, Ashok R, Kymonil KM, Subhini SA. Controlled release theophylline loaded buoyant sodium alginate microbeads for prolonged drug delivery to gastric mucosa. J pharm Res., 2010; 3: 758-762.
- Choi, B. Y., Park, H. J., Hwang, S. J., & Park, J. B. Preparation of alginate beads for floating drug delivery system: effects of CO2 gas-forming agents. International Journal of Pharmaceutics, 2002; 239: 81–91.
- Ma, N., Xu, L., Wang, Q., Zhang, X., Zhang, W., Li, Y. & Li, S. Development and evaluation of new sustained-release floating microspheres. International Journal of Pharmaceutics, 2008; 358: 82–90.
- Rohit Shah, Chandrakant Magdum, Shital Kumar Patil, Dhanya Kumar Chougule, Nilofar Naikwade. Validated Spectroscopic Method for Estimation of Aceclofenac from Tablet Formulation. Research J. Pharm. and Tech. 2008; 1(4): 430-432.
- Balaji M, Abhay A, Gyati S A, Sima S, Ramya M, Omprakash S,Niranjan K. Formulation and Characterization of Polycarbophil Coated Mucoadhesive Microspheres of Repaglinide. J. Pharm. Sci. and Res. 2015; 7(11): 972-977.
- 14. NM Bhopale, PB Aswar, NB Banarase, SS Khadabadi. Design, Development and In-vitro Evaluation of Sustain Release Rubia cordifolia Matrix Tablet. Research J. Pharm. and Tech. 2008; 1(4): 475-477.

- 15. Chakraborty Prithviraj, Dey Biplab K., Bahadur Sanjib, Thakkar Suresh, Das Sudip. Design, Development, Physicochemical and In Vitro Evaluation of Transdermal Patches Containing Verapamil Hydrochloride in Ethyl Cellulose -Povidone Matrices. Research J. Pharm. and Tech. 2009; 2(1) 168-172
- 16. VN Deshmukh, JK Jadhav, VJ Masirkar, DM Sakarkar. Formulation, Optimization and Evaluation of Controlled Release Alginate Microspheres Using Synergy Gum Blends. Research J. Pharm. and Tech. 2009; 2 (2): 324-327
- Nighute AB, Bhise SB. Preparation and Evaluation of Rifabutin Loaded Polymeric Microspheres. Research J. Pharm. and Tech. 2009; 2(2): 371-374
- R Siva Kumar, N Srisutherson, P Kumar Nallasivan, P Arulraj, R Venkatnarayanan. HPTLC Method for the Simultaneous Estimation of Aceclofenac and Diacerein in Tablets Dosage Forms. Research J. Pharm. and Tech. 2010; 3 (3): 825-827.
- 19. Balaji M, Ramyakrishna N, Hanumanaik M. Formulation Development and Characterization of Enteric Coated Tablets of Lansoprazole. Der Pharmacia Lettre, 2020; 12 (3): 22-38.
- M. Purushothaman, Sowjanya Battu, K. Jyothshna Devi, C. Madhusudhana Chetty, M. Alagusundaram, K. Mallikarjuna Rao. Formulation and Characterization of Ofloxacin Microspheres Prepared By Ionotropic Gelation Technique. Research J. Pharm. and Tech. 2010; 3 (4): 1265-1269.
- 21. Balaji M, Ramya KN, Kokkilagadda VK. Preparation and Evaluation of Esomeprazole Enteric Coated Tablets. International Journal of Pharmacy and Pharmaceutical Research. 2020; 18: 16-30.
- 22. Shah, V. P., Tsong, Y., Sathe, P., & Liu, J.-P. In vitro dissolution profile comparison Statistics and analysis of the similarity factor, f 2. Pharmaceutical Research, 1998; 15: 889–896
- 23. Balaji M, Vikas J, Ramya KN, Monika G. Formulation Development and Characterization of controlled release core in cup matrix tablets of venlafaxine HCl. Current Drug Therapy. 2020; 15(5): 503-511.